Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16978350 | 0.85 | TSHR (0.40) | TSHRPPARDTP53TDP1CA12 | |
| SCHEMBL15438714 | 0.83 | TSHR (0.43) | TSHRPPARDTP53TDP1CA12 | |
| SCHEMBL805146 | 0.82 | TSHR (0.34) | TSHRPPARDTP53TDP1CA12 | |
| SCHEMBL23457672 | 0.81 | TSHR (0.34) | TSHRPPARDCA12CA1CA2 | |
| SCHEMBL6823520 | 0.81 | PPARD (0.48) | TSHRPPARDTP53TDP1CA12 | |
| SCHEMBL27617158 | 0.81 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL25582825 | 0.81 | TSHR (0.35) | TSHRPPARDTP53TDP1CA12 | |
| SCHEMBL15438678 | 0.80 | TSHR (0.41) | TSHRPPARD | |
| SCHEMBL421908 | 0.79 | DGAT1 (0.35) | CA12CA2L3MBTL1CYP2D6 | |
| SCHEMBL16047 | 0.77 | TSHR (0.48) | TSHRPPARDTP53TDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 984 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206703-A1 | PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)METHANOL | MERCK SHARP & DOHME LLC (US) | 2025-06-26 | — | — | US | claimed |
| CN-120119112-A | Method for recovering aluminum matrix from aluminum target containing indium-tin solder | 新疆众和股份有限公司 | 2025-06-10 | — | — | CN | claimed |
| EP-4504703-A1 | PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)METHANOL | Merck Sharp & Dohme LLC (US) | 2025-02-12 | — | — | EP | claimed |
| WO-2023192170-A1 | PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)METHANOL | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | WO | claimed |
| CN-112384493-B | Process for preparing fused tricyclic gamma-amino acid derivatives and intermediates | 四川海思科制药有限公司 | 2023-06-06 | — | — | CN | claimed |
| US-20220025424-A1 | COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE AMINOCYCLOPROPANES | IMAGO BIOSCIENCES, INC. | 2022-01-27 | — | — | US | claimed |
| WO-2020029762-A1 | PREPARATION METHOD FOR FUSED TRICYCLIC γ-AMINO ACID DERIVATIVE AND INTERMEDIATE THEREOF | 四川海思科制药有限公司 | 2020-02-13 | — | — | WO | claimed |
| CN-109824645-A | Warfarin haptens and artificial antigen and the preparation method and application thereof | 中国农业大学 | 2019-05-31 | — | — | CN | claimed |
| WO-2018035249-A1 | COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE AMINOCYCLOPROPANES | IMAGO BIOSCIENCES, INC. (US) | 2018-02-22 | — | — | WO | claimed |
| CN-103789055-B | M15 methanol gasoline vapor pressure stabilizer | GANSU SANGTIAN CLEAN ENERGY DEV CO LTD | 2015-06-17 | — | — | CN | claimed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | claimed |
| US-7265229-B2 | Method for synthesizing macrosphelides | LEAD CHEMICAL CO., LTD. (JP) | 2007-09-04 | — | — | US | claimed |
| US-20060030720-A1 | Method for synthesizing macrosphelides | LEAD CHEMICAL CO., LTD. (JP) | 2006-02-09 | — | — | US | claimed |
| JP-57200396-A | — | — | None | — | — | JP | disclosed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-0405116-A2 | Phenylalkan(en)oic acids | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-01-02 | — | — | EP | disclosed |
| JP-S57200396-A | PREPARATION OF ALPHA-AMINOPHOSPHONOACETATES | KYOWA HAKKO KOGYO CO LTD | 1982-12-08 | — | — | JP | disclosed |
| US-4130659-A | Polyprenyl carboxylic acid compound and hypotensive agent containing it as active ingredient | EISAI CO., LTD. (JP) | 1978-12-19 | — | — | US | disclosed |
| US-4107193-A | HYPOTENSIVE | EISAI CO., LTD. (JP) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137680-A1 | NOVEL COMPOUNDS | CCR1, CCR4, CCR3 | TSHR 3430/4885PPARD 2857/4885TP53 2073/4885 |
| US-20060030720-A1 | Method for synthesizing macrosphelides | ADH1C, HPD, HSD17B12 | TSHR 1594/4885PPARD 278/4885TP53 4220/4885 |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | CCR1, CCR2, CBR1 | TSHR 2729/4885PPARD 2093/4885TP53 3186/4885 |
| US-20250206703-A1 | PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)METHANOL | ADH1C, ADH1A, CYP2S1 | TSHR 2880/4885PPARD 2043/4885TP53 3903/4885 |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | TSHR 3592/4885PPARD 480/4885TP53 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.